Abionyx Pharma (FRA:609) Other Current Payables: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:609 Abionyx Pharma FRA:609
19 GF Score
Price €1.88
GF Value €0.83
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma Other Current Payables?

Abionyx Pharma FRA:609 +3.41% 19 Other Current Payables is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:609 with a GF Score™ of 19/100 and a GF Value™ of €0.83 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Abionyx Pharma's Other Current Payables for the quarter that ended in Dec. 2025 was €0.00 Mil.

Abionyx Pharma's quarterly Other Current Payables stayed the same from Dec. 2024 (€0.00 Mil) to Jun. 2025 (€0.00 Mil) but then increased from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Abionyx Pharma's annual Other Current Payables increased from Dec. 2023 (€-0.00 Mil) to Dec. 2024 (€0.00 Mil) and increased from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Abionyx Pharma Other Current Payables Related Terms

Abionyx Pharma Other Current Payables Historical Data

* Premium members only.

The historical data trend for Abionyx Pharma's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abionyx Pharma Other Current Payables Chart

Abionyx Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00

Abionyx Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00
FRA:609
19GF Score
Abionyx Pharma FRA:609
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abionyx Pharma Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.00 Mil mean?
Abionyx Pharma (FRA:609) has a Other Current Payables of €0.00 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Abionyx Pharma and its competitors.
Is Abionyx Pharma's Other Current Payables too high?
Abionyx Pharma's current Other Current Payables is €0.00 Mil. Overall, Abionyx Pharma has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's Other Current Payables compare to VRTX and REGN?
Abionyx Pharma's Other Current Payables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Abionyx Pharma and its competitors. Abionyx Pharma's current Other Current Payables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (FRA:609) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.83, compared to a current price of €1.88 — trading 126.7% above its estimated fair value. The current Other Current Payables is €0.00 Mil. Abionyx Pharma's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Abionyx Pharma (FRA:609), the current Other Current Payables is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abionyx Pharma (FRA:609) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €1.88 is trading 126.7% above its estimated GF Value™ of €0.83. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for FRA:609:

  • Other Current Payables: €0.00 Mil
  • GF Value™: €0.83 vs. price of €1.88 (126.7% above fair value)
  • GF Score™: 19/100 with 4 warning signs

No single metric tells the full story. See the FRA:609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abionyx Pharma Business Description

Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
19GF Score

Get the complete analysis for FRA:609

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.88
Price
€0.83
GF Value